Table 1.
Baseline characteristics of study participants
| Variable | CYC (N=73) | MMF (N=69) |
|---|---|---|
| Age (years)- Mean (SD) | 52.0 (9.8) | 52.6 (9.7) |
| Female- % | 78.1% | 69.6% |
| SSc Duration (years)- Mean (SD) | 2.5 (1.8) | 2.6 (1.7) |
| Diffuse SSc- % | 54.8% | 62.3% |
| FVC % Predicted- Mean (SD) | 66.5 (9.9) | 66.5 (8.3) |
| DLCO % Predicted- Mean (SD) | 54.1 (14.1) | 54.0 (11.1) |
| MRSS- Mean (SD) | 14.0 (10.6) | 15.3 (10.4) |
| GIT 2.0 Reflux Score- Mean (SD) | 0.5 (0.1) | 0.6 (0.1) |
| PPI Use- % | 78.1% | 79.7% |
| QLF, % WL- Mean ± SD | 8.4 ± 7.3 | 8.9 ± 7.1 |
| QILD, % WL- Mean ± SD | 30.8 ± 14.4 | 29.3 ± 14.1 |
Abbreviations: CYC=cyclophosphamide; MMF=mycophenolate; SSc=systemic sclerosis; FVC=forced vital capacity; DLCO=diffusing capacity for carbon monoxide; mRSS=modified Rodnan skin score; PPI=proton pump inhibitor; QLF=quantitative lung fibrosis; QILD=quantitative interstitial lung disease; WL=whole lung.